The first Isomorphic Labs clinical trial has no public start date as of 18 November 2026. In January, founder and chief executive Sir Demis Hassabis targeted first trials by the end of 2026. The company’s newest statement does not repeat that date.
That statement came on 17 November 2026, when the London-based company announced a $5bn Series C round. Isomorphic said the money will help move its drug candidates toward clinical trials. However, the release names no candidate, no disease and no trial date.
When Will the First Isomorphic Labs Clinical Trial Start?
On the public record, the answer is not yet known. Speaking at the World Economic Forum in Davos, Hassabis said first trials were expected by the end of 2026. Reuters reported that target on 20 January 2026 and described it as a delay. According to the same report, Hassabis had earlier pointed to trials by the end of 2025.
The Series C release, dated London, 17 November 2026, is more measured. It says internal oncology and immunology programmes have shown positive preclinical results. Partnered programmes have done so too, according to the company. Isomorphic describes those results as “setting the stage for clinical entry”.
The release does not include supporting data, and it names no individual molecule. A search of the company’s news page on 18 November 2026 found no announcement of a trial authorisation. The same search found no announcement of a first patient dosed.
A trial could therefore still begin before the year ends. Nevertheless, the November release does not restate that aim. Confirmation of an Isomorphic Labs clinical trial will most likely come from the company or a public registry.
What the $5bn Series C Will Fund
Greenoaks and Sequoia Capital co-led the oversubscribed round. Andreessen Horowitz joined as a new investor, and Alphabet continued its investment. Existing backers Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund also took part.
According to the release, the proceeds will scale IsoDDE, the company’s proprietary drug design engine. They will also expand its pipeline of AI-designed therapeutic candidates. In addition, the money will build what Isomorphic calls AI-first translational and clinical development infrastructure.
That last item matters most for anyone tracking the timeline. Clinical infrastructure is the step between preclinical results and dosing people. Even so, the release gives no date for an Isomorphic Labs clinical trial.
Hassabis said in the release: “Our drug design engine is generating molecules with unprecedented precision and speed.” Max Jaderberg, president of Isomorphic Labs, said: “Every week we are making repeatable scientific advancements enabled by our models.”
The company did not disclose a valuation. Nor did it say how the round will be split between clinical work and platform development.
How Isomorphic Labs Reached This Point
Isomorphic was founded in 2021 as a spinout from Google DeepMind. It is headquartered in London, with offices in Cambridge, Massachusetts, and Lausanne, Switzerland.
The Series C follows a $2.1bn Series B, announced on 12 May 2026 and led by Thrive Capital. European Biotechnology Magazine puts disclosed funding at $7.7bn across three rounds since March 2025.
Pharma partnerships
The company’s first pharma partnerships came in January 2024, with Eli Lilly and Novartis. Isomorphic said then that it would receive $45m upfront from Lilly and $37.5m upfront from Novartis. It valued the two deals together at nearly $3bn, excluding royalties.
Novartis later expanded its collaboration, in February 2025, adding up to three further research programmes. Then, on 20 January 2026, Johnson & Johnson signed a multi-target, cross-modality research collaboration. Isomorphic did not disclose financial terms for that deal.
The Series C release does not say whether the first candidate to reach patients will be internal or partnered. That distinction could shape who announces the first trial.
Clinical leadership
Isomorphic appointed Dr Ben Wolf as chief medical officer on 17 June 2025. At the same time, it established a US presence in Cambridge. The company published a strategy essay on 29 September 2026. It wrote: “Our preclinical data is helping us to gear up for clinical developments.”
What the Platform Has Shown So Far
So far, the evidence Isomorphic has published concerns its models rather than its medicines. In February 2026, it released a technical report on IsoDDE. The company said the engine “more than doubles the accuracy of AlphaFold 3” on the hardest protein-ligand cases. Those cases come from the Runs N’ Poses benchmark.
The same report claimed a 2.3-fold gain over AlphaFold 3 on a novel antibody-antigen test set. The company presented these results as a technical report. Its page does not state that they were peer reviewed.
The September essay went further, describing AI agents designing molecules autonomously over two to four days. It said one agent-designed molecule “successfully modulates the biological target with good properties”. However, the essay gave no potency values and named no target.
These are laboratory and computational results. None of them yet shows how an Isomorphic molecule behaves in people.
What Has to Happen Before a First Patient Is Dosed
The US route
In the United States, a sponsor must first file an investigational new drug (IND) application. FDA guidance states that an IND may take effect 30 days after the agency receives it. That applies unless the FDA notifies the sponsor of a clinical hold. Until the IND takes effect, investigators may not give the drug to people.
The UK route
Any Isomorphic Labs clinical trial in the UK would need regulatory and ethics approval. Updated UK clinical trials regulations came into force on 28 April 2026. The Health Research Authority said combined review by the MHRA and HRA takes an average of 41 days.
The FDA does not routinely publish IND filings. As a result, the first public signal is often a company announcement or a registry entry.
Why the Clinical Milestone Matters for AI Drug Discovery
BioSpace described the round as a record for biotech venture fundraising. It is also large against the UK market.
The BioIndustry Association’s Q3 2026 finance report recorded £2.84bn of UK biotech venture capital in 2026’s first nine months. Isomorphic’s £1.6bn Series B made up about 55 per cent of that total. The new $5bn round alone exceeds that nine-month figure. The wider picture is set out in an analysis of UK biotech venture capital in Q3 2026.
In effect, investors and partners are funding a platform before a product. A first Isomorphic Labs clinical trial would offer the first human test of molecules designed with IsoDDE.
Other AI-led developers already have molecules in human studies, as the review of AI-discovered drugs in 2026 shows. By contrast, Isomorphic’s standing so far rests on its models, partnerships and funding.
What Would Settle the Question
Three kinds of disclosure would answer the timing question. The first is a company announcement of an IND, a UK authorisation or a first patient dosed. The second is a public registry record naming Isomorphic as sponsor. The third is a partner disclosing a clinical start for a molecule from its collaboration.
Until one of those appears, the end-2026 target rests on a January statement reported by Reuters. The 17 November release neither repeats nor withdraws it.
Readers tracking the first Isomorphic Labs clinical trial should treat late 2026 as an aim, not a confirmed date. Any announcement before 31 December would meet the target Hassabis set in Davos.














